Key clinical point: The novel calcipotriol (CAL)/betamethasone dipropionate (BDP) PAD-cream offered greater benefits than the currently available topical suspension/gel (CAL/BDP TS) in terms of efficacy and patient quality of life along with favorable safety in plaque psoriasis.
Major finding: At 8 weeks, CAL/BDP PAD-cream vs CAL/BDP TS was associated with a significantly higher Physician's Global Assessment success rate (43.2% vs 31.9%; P < .0001), mean percent reduction in modified Psoriasis Area Severity Index (64.6% vs 56.4%; P < .0001), and Dermatology Life Quality Index 0/1 response rate (43.8% vs 34.2%; P = .0005) and no adverse drug reaction with a frequency greater than 1%.
Study details: This is a pooled analysis of 2 phase 3 trials consisting of a combined 1,271 patients with mild-to-moderate plaque psoriasis, treated with either CAL/BDP PAD-cream (n=551), CAL/BDP TS (n=542), or vehicle (n=178).
Disclosures: Both trials were sponsored by MC2 Therapeutics, Denmark. Some of the authors including the lead author received investigator honoraria for phase 3 trials from MC2, and the rest are employees of MC2.
Source: Pinter A et al. J Eur Acad Dermatol Venereol. 2021 Oct 10. doi: 10.1111/jdv.17734 .